Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Kitov Pharma Ltd is a development stage biopharmaceutical company. It focuses on the development of KIT-302, a combination drug for the simultaneous treatment of two clinical conditions pain caused by osteoarthritis and hypertension; and NT219 which is a fixed-dose combination of two drug products that treat osteoarthritis pain and hypertension simultaneously. The company's operating segment include Pain and Hypertension and Oncology, It generates maximum revenue from the Pain and Hypertension segment.
Tel Aviv, 6701101, Israel